Clinical and genomic factors associated with elacestrant outcomes in ESR1-mutant metastatic breast cancer open access

In a real-world analysis of more than 700 patients with ESR1-mutant metastatic breast cancer, investigators found that elacestrant treatment durations supported the routine use of elacestrant monotherapy in appropriately selected patients. They also found that results for single-agent activity in patients with concurrent ESR1 and PI3K pathway mutations were comparable with outcomes observed in phase III studies.